PLXP Stock Overview
PLx Pharma Inc., a specialty pharmaceutical company, focuses on developing the PLxGuard drug delivery system to provide various products in the United States.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$9.88|
|52 Week High||US$21.50|
|52 Week Low||US$5.01|
|1 Month Change||-26.16%|
|3 Month Change||-41.40%|
|1 Year Change||76.43%|
|3 Year Change||140.39%|
|5 Year Change||n/a|
|Change since IPO||13.56%|
Recent News & Updates
Most Shareholders Will Probably Find That The CEO Compensation For PLx Pharma Inc. (NASDAQ:PLXP) Is Reasonable
Despite strong share price growth of 248% for PLx Pharma Inc. ( NASDAQ:PLXP ) over the last few years, earnings growth...
We're Interested To See How PLx Pharma (NASDAQ:PLXP) Uses Its Cash Hoard To Grow
Just because a business does not make any money, does not mean that the stock will go down. By way of example, PLx...
PLx Pharma: First Commercial Launch Makes It Attractive
PLx Pharma has just launched its lead product VAZALORE, the first liquid-filled aspirin capsule. The Company’s PLxGuard drug delivery platform has the potential to be used with other approved or under-development drugs and NSAIDs. The Company has a comfortable cash runway to carry through the VAZALORE manufacturing and distribution while advancing the pipeline for existing and prospective candidates.
|PLXP||US Pharmaceuticals||US Market|
Return vs Industry: PLXP exceeded the US Pharmaceuticals industry which returned 18.6% over the past year.
Return vs Market: PLXP exceeded the US Market which returned 24.7% over the past year.
|PLXP Average Weekly Movement||11.4%|
|Pharmaceuticals Industry Average Movement||9.2%|
|Market Average Movement||5.9%|
|10% most volatile stocks in US Market||15.1%|
|10% least volatile stocks in US Market||2.2%|
Stable Share Price: PLXP is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: PLXP's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
PLx Pharma Inc., a specialty pharmaceutical company, focuses on developing the PLxGuard drug delivery system to provide various products in the United States. The company’s lead product candidates are Vazalore 325 mg and Vazalore 81 mg, which are formulations of aspirin that use the PLxGuard delivery system, which provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy based on physician recommendation, with fast, reliable, and predictable platelet inhibition as compared to enteric-coated aspirin, as well as reduces the risk of stomach erosions and ulcers as compared with immediate-release aspirin, after seven days of treatment. Its product pipeline also includes other oral nonsteroidal anti-inflammatory drugs using the PLxGuard drug delivery system, such as PL1200 Ibuprofen 200 mg and PL1200 Ibuprofen 400 mg, which are in Phase I clinical stage for pain and inflammation, as well as PL1100 Ibuprofen 400 mg.
PLx Pharma Fundamentals Summary
|PLXP fundamental statistics|
Is PLXP overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PLXP income statement (TTM)|
|Cost of Revenue||US$3.91m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-2.20|
|Net Profit Margin||-917.51%|
How did PLXP perform over the long term?See historical performance and comparison
Is PLx Pharma undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate PLXP's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate PLXP's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: PLXP is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: PLXP is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PLXP's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PLXP is overvalued based on its PB Ratio (8.8x) compared to the US Pharmaceuticals industry average (2.7x).
How is PLx Pharma forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PLXP is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PLXP is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PLXP is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PLXP's revenue (55.9% per year) is forecast to grow faster than the US market (10.1% per year).
High Growth Revenue: PLXP's revenue (55.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PLXP's Return on Equity is forecast to be high in 3 years time
How has PLx Pharma performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PLXP is currently unprofitable.
Growing Profit Margin: PLXP is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PLXP is unprofitable, and losses have increased over the past 5 years at a rate of 37.4% per year.
Accelerating Growth: Unable to compare PLXP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PLXP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.2%).
Return on Equity
High ROE: PLXP has a negative Return on Equity (-122.61%), as it is currently unprofitable.
How is PLx Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: PLXP's short term assets ($88.6M) exceed its short term liabilities ($7.4M).
Long Term Liabilities: PLXP's short term assets ($88.6M) exceed its long term liabilities ($37.4M).
Debt to Equity History and Analysis
Debt Level: PLXP is debt free.
Reducing Debt: PLXP currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PLXP has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: PLXP has sufficient cash runway for 2.8 years if free cash flow continues to reduce at historical rates of 27.4% each year.
What is PLx Pharma current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PLXP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PLXP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PLXP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PLXP's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PLXP's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Natasha Giordano (61 yo)
Ms. Natasha Giordano serves as Independent Director at Matinas BioPharma Holdings, Inc. since September 14, 2020. She has been Chief Executive Officer and President at PLx Pharma Inc. since January 1, 2016...
CEO Compensation Analysis
Compensation vs Market: Natasha's total compensation ($USD2.44M) is above average for companies of similar size in the US market ($USD1.09M).
Compensation vs Earnings: Natasha's compensation has increased whilst the company is unprofitable.
Experienced Management: PLXP's management team is considered experienced (4.2 years average tenure).
Experienced Board: PLXP's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 200.7%.
PLx Pharma Inc.'s employee growth, exchange listings and data sources
- Name: PLx Pharma Inc.
- Ticker: PLXP
- Exchange: NasdaqCM
- Founded: 2002
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$272.067m
- Shares outstanding: 27.54m
- Website: https://plxpharma.com
Number of Employees
- PLx Pharma Inc.
- 9 Fishers Lane
- Suite E
- New Jersey
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/11/25 00:07|
|End of Day Share Price||2021/11/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.